bit.bio Glutamatergic neurons PINK1 Q456X Hom ICC MAP2 staining

cat no | io1076

ioGlutamatergic Neurons PINK1 Q456X/Q456X

Human iPSC-derived Parkinson's disease model

ioGlutamatergic Neurons PINK1 Q456X/Q456X are opti‑ox deterministically programmed glutamatergic neurons carrying a genetically engineered homozygous Q456X mutation in the PINK1 gene encoding the protein PTEN induced putative kinase 1. These cells offer a rapidly maturing, disease relevant system for investigating the role of PINK1 Q456X mutation in early-onset Parkinson's disease (PD).

Place your order

Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.

Vial size

Quantity

Price

per vial

Add to basket

Request a quote Talk to an expert

For academic discounts, sample requests or bulk pricing inquiries, contact us

Benchtop benefits

Make True Comparisons

Pair the Parkinson's disease model cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of the PINK1 nonsense mutation on early-onset PD.

Scalable

With opti-ox technology, we can make billions of consistently deterministically programmed cells, surpassing the demands of industrial workflows.

Quick

The disease model cells and wild-type control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Highly characterised and defined

ioGlutamatergic Neurons PINK1 Q456X/Q456X express neuron-specific markers comparably to the wild-type control

bit.bio Glutamatergic Neurons PINK1 Q456X hom ICC marker staining TUBB3, MAP2, VGLUT2

Immunofluorescent staining on day 11 post revival demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons PINK1 Q456X/Q456X clones compared to the genetically matched control. 100X magnification.

ioGlutamatergic Neurons PINK1 Q456X/Q456X form structural neuronal networks by day 11

bit.bio Glutamatergic Neurons PINK1 Q456X hom neuronal morphology

ioGlutamatergic Neurons PINK1 Q456X/Q456X mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; 100X magnification.

ioGlutamatergic Neurons PINK1 Q456X/Q456X demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming

bit.bio Glutamatergic Neurons PINK Q456X hom gene expression RT-qPCR

Gene expression analysis demonstrates that ioGlutamatergic Neurons PINK1 Q456X/Q456X and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, while expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Disease-related PINK1 is expressed in ioGlutamatergic Neurons PINK1 Q456X/Q456X following deterministic programming

bit.bio PINK1 gene expression in Glutamatergic Neurons PINK Q456X hom Parkinson's disease model

RT-qPCR analysis demonstrates expression of the PINK1 gene in both wild type ioGlutamatergic Neurons (WT Control) and ioGlutamatergic Neurons PINK1 Q456X/Q456X at day 11 post revival. Data normalised to HMBS, n=2 replicates.

Cells arrive ready to plate

bit.bio Glutamatergic Neurons user manual timeline

ioGlutamatergic Neurons PINK1 Q456X/Q456X are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Industry leading seeding density

bit.bio Glutamatergic Neurons with low minimum seeding density

The recommended minimum seeding density is 30,000 cells/cm², compared to up to 250,000 cells/cm² for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Product information

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male, age 55-60 years old (skin fibroblast)

Vial size

Small: >1 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox deterministic cell programming

Recommended seeding density

30,000 cells/cm²

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Homozygous Q456X nonsense mutation in the PINK1 gene

Applications

Parkinson's disease research
Drug discovery and development
Disease modelling

Available clones

io1075 | PINK1 Q456X/Q456X (CL49)
io1076 | PINK1 Q456X/Q456X (CL77)

Product use

ioCells are for research use only

Supporting documentation

User Manual

Limited Use License & Statement of Use

Product resources

Application note

Producing 3D Neuronal Microtissues for Preclinical Drug Screening using ioGlutamatergic Neurons

V1
2024
bit.bio
Inventia

Download

Application note

Sartorius application note - Advanced in vitro Modeling of Human iPSC-derived Neuronal Mono- and Co-cultures with Microglia

Trigg et al.,
Sartorius
2024

Download

Brochure

ioGlutamatergic Neurons

bit.bio

Download

User manual

ioGlutamatergic Neurons Wild Type and related disease models | User Manual

V11

bit.bio

2024

Download

Publication

Circadian clocks in human cerebral organoids

Rzechorzek, et al

bioRxiv

2024

Featuring opti-oxenabled microglia male iPS cell line and opti-ox enabled glutamatergic neurons iPS cell line

Poster

Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease

Smith, et al.
bit.bio
2024

Download

Publication

Schizophrenia risk gene ZNF804A controls ribosome localization and synaptogenesis in developing human neurons

Deepak P. Srivastava, et al

bioRxiv

2024

Featuring opti-ox enabled glutamatergic neurons iPS cell line

Case study

Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons

Professor Deepak Srivastava

Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders

King’s College London

Download

Webinar

Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | bit.bio

Javier Conde-Vancells | Director Product Management | bit.bio

Watch now

Publication

Rewiring of the promoter-enhancer interactome and regulatory landscape in glioblastoma orchestrates gene expression underlying neurogliomal synaptic communication

Chakraborty et al
Nature Communications
2023

Featuring ioGlutamatergic Neurons